Tags

Type your tag names separated by a space and hit enter

Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies.
BMC Gastroenterol 2012; 12:165BG

Abstract

BACKGROUND

Green tea has shown the role of chemoprevention for cancer. Recently, several studies suggested that green tea intake may have effect on esophageal cancer risk, whereas the results were inconsistent.

METHODS

We performed a meta-analysis of all English and Chinese language studies of green tea consumption and esophageal cancer risk indexed in Medline, Embase, the Science Citation Index, the Chinese Biomedical Database and Wanfang Data from 1980 to June 2012. After reviewing each study, extracting data, and evaluating heterogeneity (Chi-square-based Q test and Ι2) and publication bias (Begg and Egger test), a meta-analysis was performed to evaluate the association between high/medium/low green tea consumption and non-drinking esophageal cancer risk. Pooled relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs) were calculated using the fixed- or random-effect models.

RESULTS

Ten eligible epidemiologic studies including 33731 participants and 3557 cases for esophageal cancer were included. Eight of which were case-control studies, and two were cohort studies. Overall, there were no association between high/medium/low green tea consumption and non-drinking risk of esophageal cancer (High: highest vs non-drinker: RR/OR = 0.76, 95% CI: 0.49 to 1.02. Medium: drinker vs non-drinker: RR/OR = 0.86, 95% CI: 0.70 to 1.03. Low: lowest vs non-drinker: RR/OR = 0.83, 95% CI: 0.58 to 1.08). When stratified analyses according to study design (case-control and cohort studies), country (China and Japan), participates source (population-based and hospital-based case-control), and gender (female and male), there were significant association between high/medium/low green tea consumption and non-drinking risk of esophageal cancer among female (High: RR/OR = 0.32, 95% CI: 0.10 to 0.54. Medium: RR/OR = 0.43, 95% CI: 0.21 to 0.66. Low: RR/OR = 0.45, 95% CI: 0.10 to 0.79), but not the others.

CONCLUSIONS

We did not found significant association between green tea consumption and non-drinking esophageal cancer risk, but an evidence of protective effect was observed among female.

Authors+Show Affiliations

National Hepatobiliary & Enteric Surgery Research Center of South University, 87 Xiangya Road, Changsha, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

23170950

Citation

Zheng, Ping, et al. "Green Tea Consumption and Risk of Esophageal Cancer: a Meta-analysis of Epidemiologic Studies." BMC Gastroenterology, vol. 12, 2012, p. 165.
Zheng P, Zheng HM, Deng XM, et al. Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies. BMC Gastroenterol. 2012;12:165.
Zheng, P., Zheng, H. M., Deng, X. M., & Zhang, Y. D. (2012). Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies. BMC Gastroenterology, 12, p. 165. doi:10.1186/1471-230X-12-165.
Zheng P, et al. Green Tea Consumption and Risk of Esophageal Cancer: a Meta-analysis of Epidemiologic Studies. BMC Gastroenterol. 2012 Nov 21;12:165. PubMed PMID: 23170950.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies. AU - Zheng,Ping, AU - Zheng,Hai-Ming, AU - Deng,Xing-Ming, AU - Zhang,Yang-de, Y1 - 2012/11/21/ PY - 2012/02/23/received PY - 2012/10/29/accepted PY - 2012/11/23/entrez PY - 2012/11/23/pubmed PY - 2013/6/15/medline SP - 165 EP - 165 JF - BMC gastroenterology JO - BMC Gastroenterol VL - 12 N2 - BACKGROUND: Green tea has shown the role of chemoprevention for cancer. Recently, several studies suggested that green tea intake may have effect on esophageal cancer risk, whereas the results were inconsistent. METHODS: We performed a meta-analysis of all English and Chinese language studies of green tea consumption and esophageal cancer risk indexed in Medline, Embase, the Science Citation Index, the Chinese Biomedical Database and Wanfang Data from 1980 to June 2012. After reviewing each study, extracting data, and evaluating heterogeneity (Chi-square-based Q test and Ι2) and publication bias (Begg and Egger test), a meta-analysis was performed to evaluate the association between high/medium/low green tea consumption and non-drinking esophageal cancer risk. Pooled relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs) were calculated using the fixed- or random-effect models. RESULTS: Ten eligible epidemiologic studies including 33731 participants and 3557 cases for esophageal cancer were included. Eight of which were case-control studies, and two were cohort studies. Overall, there were no association between high/medium/low green tea consumption and non-drinking risk of esophageal cancer (High: highest vs non-drinker: RR/OR = 0.76, 95% CI: 0.49 to 1.02. Medium: drinker vs non-drinker: RR/OR = 0.86, 95% CI: 0.70 to 1.03. Low: lowest vs non-drinker: RR/OR = 0.83, 95% CI: 0.58 to 1.08). When stratified analyses according to study design (case-control and cohort studies), country (China and Japan), participates source (population-based and hospital-based case-control), and gender (female and male), there were significant association between high/medium/low green tea consumption and non-drinking risk of esophageal cancer among female (High: RR/OR = 0.32, 95% CI: 0.10 to 0.54. Medium: RR/OR = 0.43, 95% CI: 0.21 to 0.66. Low: RR/OR = 0.45, 95% CI: 0.10 to 0.79), but not the others. CONCLUSIONS: We did not found significant association between green tea consumption and non-drinking esophageal cancer risk, but an evidence of protective effect was observed among female. SN - 1471-230X UR - https://www.unboundmedicine.com/medline/citation/23170950/Green_tea_consumption_and_risk_of_esophageal_cancer:_a_meta_analysis_of_epidemiologic_studies_ L2 - https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-12-165 DB - PRIME DP - Unbound Medicine ER -